Professionals specializing in different aspects of drug development will exchange ideas and information at MDA’s scientific conference April 21-24
posted on April 18, 2013 - 10:03am
The Muscular Dystrophy Association’s annual conference being held in Washington, D.C., on April 21-24, 2013, is centered on the theme Therapy Development for Neuromuscular Diseases: Translating Hope into Promise.
Riluzole and tirasemtiv — two drugs with connections to other neuromuscular disorders — are being tested as potential treatments for spinal muscular atrophy
posted on April 15, 2013 - 9:00am
In the search for therapies for spinal muscular atrophy (SMA), researchers are testing two drugs with connections to other neuromuscular disorders: riluzole, which is approved for use in amyotrophic lateral sclerosis (ALS); and tirasemtiv, which is already in testing for ALS and
In a phase 2a trial in myasthenia gravis, Cytokinetics’ drug tirasemtiv showed dose-related beneficial effects and no serious adverse events
posted on December 12, 2012 - 9:10am
The experimental drug tirasemtiv has shown promise in a phase 2a clinical trial in 32 people with myasthenia gravis (MG). Improvements in general and respiratory muscle function occurred in response to the medication.
Six hours after receiving a single, oral dose of tirasemtiv, study participants showed improvements on a standardized scale of MG severity (the Quantitative MG score) and in forced...